With over 30 years experience serving over 600 clients including all the world leading pharmaceutical and biotech companies, Almac is a financially stable and privately owned organisation employing 2,200 dedicated professionals within the US & EU.
Almac's aim is to provide the most comprehensive range of integrated drug development solutions to enable accelerated development from research through to commercialisation.
Services Offered
Almac's truly integrated approach provides a seamless, fast and efficient route from drug discovery through to market.
Research
Almac provide genomics based solutions, informing drug discovery and enabling personalised medicine. Our services include:
Biomarker Discovery & Validation
Bioinformatic Solutions
Genomic Services
Medicinal Chemistry Support
Chemical & Pharmaceutical Development
Almac accelerate the development of customers' drug candidates through the effective integration of science and manufacturing to provide drug substance & product:
API Supply
Solid State Services
Isotope Labelling
Product Development
Analytical Services
Accelerated First In Man
Clinical Development
Almac is a recognised leader in the preparation of clinical trial supplies. Our technology solutions provide unrivalled access to data critical to the efficient management of clinical trials:
Comparator Blinding
Packaging & Labelling
QP Release
Global Distribution
IVR / Web
ePRO
EDC
Commercial
Almac provides solid dosage form commercial manufacture and packaging for EU & US markets. Commercial support services facilitate EU market access for non-EU product:
Commercial Manufacturing
Commercial Packaging
Commercial Support
New Developments
Almac is investing $100m in a new North American headquarters facility based in Pennsylvania. Construction of the facility has commenced and it will be fully operational in 2010.
The number of distribution depots now managed by Almac Clinical Services has increased from 14 last year to 21 depots in 19 countries. We expect further depots to be added going forward, which will be a pivotal factor in our distribution strategy.
Almac Clinical Services are continuing the expansion of our European site with a new purpose-built facility for controlled drug and refrigerated storage. The facility will provide up to 800 additional pallet spaces for refrigerated material. This coupled with the recent 70,000 cu. ft expansion of our US storage facility enables Almac to continue catering for the continued growth in IMP cold chain services.
The introduction of Solid State Services allows our customers to rapidly optimise the physical form of drug substance and bioavailability of drug product.
Almac is also adding a further 16,000 sq ft of analytical capacity at its European headquarters in Northern Ireland. The $18m self financed investment is a 3-floor extension to its current commercial manufacture building.